Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun 25:15:245.
doi: 10.1186/s12913-015-0925-x.

Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures

Affiliations

Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures

Xue Song et al. BMC Health Serv Res. .

Abstract

Background: The high acute costs of cardiovascular disease and acute cardiovascular events are well established, particularly in terms of direct medical costs. The costs associated with lost work productivity have been described in a broad sense, but little is known about workplace absenteeism or short term disability costs among high cardiovascular risk patients. The objective of this study was to quantify workplace absenteeism (WA) and short-term disability (STD) hours and costs associated with cardiovascular events and related clinical procedures (CVERP) in United States employees with high cardiovascular risk.

Methods: Medical, WA and/or STD data from the Truven Health MarketScan® Research Databases were used to select full-time employees aged 18-64 with hyperlipidemia during 2002-2011. Two cohorts (with and without CVERP) were created and screened for medical, drug, WA, and STD eligibility. The CVERP cohort was matched with a non-CVERP cohort using propensity score matching. Work loss hours and indirect costs were calculated for patients with and without CVERP and by CVERP type. Wages were based on the 2013 age-, gender-, and geographic region-adjusted wage rate from the United States Bureau of Labor Statistics.

Results: A total of 5,808 WA-eligible, 21,006 STD-eligible, and 3,362 combined WA and STD eligible patients with CVERP were well matched to patients without CVERP, creating three cohorts of patients with CVERP and three cohorts of patients without CVERP. Demographics were similar across cohorts (mean age 52.2-53.1 years, male 81.3-86.8%). During the first month of follow-up, patients with CVERP had more WA/STD-related hours lost compared with patients without CVERP (WA-eligible: 23.4 more hours, STD-eligible: 51.7 more hours, WA and STD-eligible: 56.3 more hours) (p < 0.001). Corresponding costs were $683, $895, and $1,119 higher, respectively (p < 0.001). Differences narrowed with longer follow-up. In the first month and year of follow-up, patients with coronary artery bypass graft experienced the highest WA/STD-related hours lost and costs compared with patients with other CVERP.

Conclusions: CVERP were associated with substantial work loss and indirect costs. Prevention or reduction of CVERP could result in WA and STD-related cost savings for employers.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient selection. CVERP: cardiovascular events and related clinical procedures; STD: short-term disability; WA: workplace absenteeism
Fig. 2
Fig. 2
Number and Percentage of Patients by CVERP Type at Index. CVERP: cardiovascular events and related clinical procedures; CABG: coronary artery bypass graft; HF: heart failure; IS: ischemic stroke; MI: myocardial infarction; PCI: percutaneous coronary intervention; TIA: transient ischemic attack; UA: unstable angina
Fig. 3
Fig. 3
WA and STD Hours and Costs by CVERP Type. CABG: coronary artery bypass graft; HF: heart failure; IS: ischemic stroke; MI: myocardial infarction; PCI: percutaneous coronary intervention; PPPM: per patient per month; STD: short-term disability; TIA: transient ischemic attack; UA: unstable angina; WA: workplace absenteeism

References

    1. Tarride JE, Lim M, DesMeules M, Luo W, Burke N, O’Reilly D, et al. A review of the cost of cardiovascular disease. Can J Cardiol. 2009;25:e195–202. doi: 10.1016/S0828-282X(09)70098-4. - DOI - PMC - PubMed
    1. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44. doi: 10.1161/CIR.0b013e31820a55f5. - DOI - PubMed
    1. Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff. 2007;26:38–48. doi: 10.1377/hlthaff.26.1.38. - DOI - PubMed
    1. Waters DD, Brotons C, Chiang CW, Ferrieres J, Foody J, Jukema JW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120:28–34. doi: 10.1161/CIRCULATIONAHA.108.838466. - DOI - PubMed
    1. Trogdon JG, Finkelstein EA, Nwaise IA, Tangka FK, Orenstein D. The economic burden of chronic cardiovascular disease for major insurers. Health Promot Pract. 2007;8:234–42. doi: 10.1177/1524839907303794. - DOI - PubMed

Publication types

LinkOut - more resources